Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)

Size: px
Start display at page:

Download "Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)"

Transcription

1 Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: Created by: Apprved by: Prvince-wide Immunizatin Prgram Standards and Quality Prvince-wide Immunizatin Prgram Standards and Quality Apprval Date: September 1, 2016 Revised: February 1, 2017 Manufacturer Bilgical Classificatin Indicatins fr Prvincially Funded Vaccine Nte: Fr questins related t Travel and r Fr Sale vaccine refer t AHS Travel Health and Cntracted Immunizatin Services resurces. Schedule GlaxSmithKline Inc. Inactivated Primary immunizatin fr children tw mnths up t and including 23 mnths f age when diphtheria, tetanus, acellular pertussis, pli, Hib and hepatitis B vaccines are indicated fr nn-hyprespnsive individuals. Nte: Hepatitis B vaccine indicated fr: Infants brn t hepatitis B infected mthers r whse primary caregiver is hepatitis B infected (acute cases r carriers) Infants wh are husehld cntacts f a hepatitis B carrier Infants whse families have immigrated t Canada frm areas where there is a high prevalence (8% r higher) f hepatitis B. See Hepatitis B Endemic Cuntries List Primary series fr high risk infants wh have received HBIG and/r hepatitis B vaccine at birth. Exceptin: D nt administer INFANRIX hexa t high risk infants weighing less than 2000g wh received Hepatitis B vaccine and/r HBIG at birth. These infants shuld cntinue t receive the separate Hepatitis B vaccine accrding t the schedule utlined in the Hepatitis B Vaccine Bilgical Page (#07.234). Nte: INFANRIX hexa cntains nly a regular strength dse f Hepatitis B Vaccine and is nt indicated fr infants and children requiring a duble dse f Hepatitis B vaccine. Children 2 mnths up t and including 23 mnths f age: Dse 1: 2 mnths f age Dse 2: 4 mnths f age Dse 3: 6 mnths f age Ntes: Third dse shuld nt be given t infants befre 6 mnths (24 weeks r 168 days) f age. Spacing recmmendatin fr ff schedule children is 2 mnths (8 weeks) between dses hwever, minimum intervals respecting all f the fllwing may be used: Minimum f 4 weeks between the first and secnd dse AND, Minimum f 8 weeks between the secnd and third dse AND Minimum f 4 mnths (16 weeks r 112 days) between the first and third dse. Immunizatin Prgram Standards Manual Page 1 f 5 Ppulatin, Public and Indigenus Health

2 Preferred Use Dse Rute Cntraindicatins/ Precautins N/A Where a dse f hepatitis B vaccine is given at birth, INFANRIX hexa can be used fr the subsequent dses as per the schedule indicated abve. An infant in this case wuld receive a ttal f 4 dses f hepatitis B vaccine. Where a dse f hepatitis B vaccine is given at birth, INFANRIX hexa can be used fr the secnd dse frm the age f six weeks. This spacing wuld nly be used if early immunizatin is required due t increased risk f expsure t antigens ther than Hepatitis B cntained in the vaccine. The first three dses f an immunizatin series shuld be cmpleted with the same cmbinatin prduct whenever pssible. If this is nt pssible an alternative cmbinatin may be used. Ideally a series started with INFANRIX hexa will be cmpleted with INFANRIX hexa. A series started with separate DTaP-IPV-Hib and Hepatitis B vaccine shuld be cmpleted with the separate vaccines. Exceptin as detailed abve is infants given a dse f hepatitis B vaccine at birth. The schedule and spacing cnsideratins fr this vaccine vary slightly frm thse f the individual HBV and DTaP-IPV-Hib vaccines. Ensure the apprpriate schedule is fllwed fr the vaccine(s) that are being used. The rutine 18 mnth dse will be cmpleted with a DTaP-IPV-Hib cntaining vaccine. Children wh have had pertussis infectin shuld cntinue t receive pertussis-cntaining vaccines. Children in whm invasive Hib disease develps befre 24 mnths f age shuld receive Hib vaccine as recmmended because natural disease may nt induce prtectin. Children 7 mnths up t and including 23 mnths f age wh are starting a primary series r wh have an incmplete primary series f INFANRIX hexa shuld cntinue t receive INFANRIX hexa as indicated abve. These children may need fewer dses f the Hib cmpnent; hwever, it is acceptable t give the additinal dses f Hib vaccine in this cmbinatin vaccine fr cnvenience f administratin. Individuals travelling t cuntries currently exprting and/r infected with pli may need special immunizatin dcumentatin verifying pli immunizatin. These individuals shuld cnsult with a Travel Clinic t determine what dcumentatin is required. 0.5 ml Nte: Once recnstituted, withdraw the entire cntents f the vial. IM Cntraindicatins: Knwn severe hypersensitivity t any cmpnent f INFANRIX hexa. The plunger stpper f pre-filled syringe may cntain latex. Anaphylactic reactin t a previus dse f vaccine cntaining diphtheria, tetanus, pertussis, pli, Hib r hepatitis B antigens. Encephalpathy (eg. cma, decreased level f cnsciusness, prlnged seizures) within seven days f a previus dse f a pertussis-cntaining vaccine nt attributable t anther identifiable cause. Precautins: Child Hematpietic Stem Cell Transplant (HSCT) Recipients and Children Immunizatin Prgram Standards Manual Page 2 f 5 Ppulatin, Public and Indigenus Health

3 Pssible Reactins Pregnancy Lactatin Cmpsitin Pre and Pst Slid Organ Transplant shuld nt receive INFANRIX hexa as INFANRIX hexa cntains a regular strength dse f Hepatitis B vaccine. D nt administer INFANRIX hexa t high risk infants weighing less than 2000g wh received Hepatitis B vaccine and/r HBIG at birth. These infants shuld cntinue t receive the separate Hepatitis B vaccine accrding t the schedule utlined in the Hepatitis B Vaccine Bilgical Page (#07.234). Capsular plysaccharide antigen (Hib antigen) can be detected in the urine f vaccine recipients fr up t tw weeks fllwing immunizatin with cnjugate vaccines. This phenmenn culd be cnfused with antigenuria assciated with invasive Hib infectins. Hib vaccines shuld never be given t a child yunger than six weeks f age. Data suggest that Hib cnjugate vaccines given befre six weeks f age may induce immunlgic tlerance (reduced respnse t subsequent dses). Children with neurlgic cnditins shuld be assessed carefully. If Guillain-Barré Syndrme (GBS) ccurred within eight weeks f immunizatin with a previus dse f vaccine cntaining tetanus txid, it is prudent t withhld subsequent dses f tetanus-cntaining vaccine. Thse wh develp GBS utside f this interval r have an alternative cause identified may receive subsequent dses f tetanus-cntaining vaccine. Cmmn: Apprximately 10% r mre f children receiving INFANRIX hexa will experience pain, redness, swelling at the injectin site, lss f appetite, fatigue, irritability, abnrmal crying, restlessness and fever f 38 C r greater. Apprximately 1-10% f children receiving INFANRIX hexa will experience nervusness, vmiting, diarrhea, lcal swelling at the injectin site (>50 mm), fever >39.5 C (when given at the same time as pneumcccal cnjugate vaccine), pruritus and injectin site reactins, including induratin. Rare: Upper respiratry tract infectin, smnlence, swelling f the injected limb, brnchitis, rash, dermatitis, brnchspasm. Apnea in very premature infants ( 28 weeks gestatin), thrmbcytpenia, allergic reactins, anaphylaxis, nervus system disrders, angineurtic edema, petichiae/purpura, injectin vesicles, swelling f the limb and peripheral edema. As with any immunizatin, unexpected r unusual side effects can ccur. Refer t the prduct mngraph fr mre detailed infrmatin. Nt intended fr use in adults. Nt intended fr use in adults. Each 0.5 ml dse cntains: Active Ingredients: Diphtheria txid 25 Lf Tetanus txid 10 Lf Acellular pertussis: Pertussis txid (PT) 25 mcg Filamentus haemagglutinin (FHA) 25 mcg Pertactin 8 mcg Hepatitis B 10 mcg Inactivated plimyelitis vaccine Type 1-40 DU Immunizatin Prgram Standards Manual Page 3 f 5 Ppulatin, Public and Indigenus Health

4 Bld/Bld Prducts Bvine/Prcine Prducts Latex Interchangeability Administratin with Other Prducts Appearance Type 2 8 DU Type 3 32 DU Purified plyribsyl-ribitlphsphate capsular plysaccharide (PRP) f Haemphilus influenzae type b cvalently bund t tetanus txid 10 mcg Nn-medical Ingredients: lactse sdium chlride aluminum salts water fr injectin Manufacturing residuals: Frmaldehyde Plysrbate 20 and 80 M199 (as a stabilizer) Ptassium chlride Disdium phsphate Mnptassium phsphate Glycine Nemycin sulphate Plymyxin B sulphate Aluminum phsphate 5% yeast prtein Des nt cntain human bld r bld prducts. Des nt cntain bvine r prcine prducts. Latex in plunger stpper f pre-filled syringe. The first three dses f the immunizatin series shuld be cmpleted, whenever pssible, with the same cmbinatin prduct. Hwever, if the riginal vaccine is nt knwn r nt available an alternate cmbinatin prduct may be used t cmplete the primary series, with a separate dse f Hepatitis B vaccine. Either Pediacel r Infanrix -IPV/Hib may be used interchangeably fr the furth dse. INFANRIX hexa can be given cncmitantly with pneumcccal cnjugate, MenC cnjugate, MenACWY cnjugate, rtavirus, measles, mumps, rubella and varicella vaccines. Data have shwn n clinically relevant interference in the antibdy respnse t each f the individual antigens in INFANRIX hexa Can be given at the same time as ther inactivated and live vaccine using a separate needle and syringe fr each vaccine. The same limb may be used if necessary, but different sites n the limb must be chsen The Hib cmpnent will appear as a lyphilized white pwder. The DTaP-HB-IPV cmpnent is supplied as a turbid white suspensin. The recnstituted vaccine presents as a slightly mre cludy suspensin than the liquid cmpnent alne. Strage Stre at +2 0 C t +8 0 C. D nt freeze. D nt use beynd the labeled expiry date. Stre in riginal packaging when pssible t prtect frm light. Vaccine Cde DTaP-IPV-Hib-HB Immunizatin Prgram Standards Manual Page 4 f 5 Ppulatin, Public and Indigenus Health

5 Antigen Cde Licensed fr Tetanus T Diphtheria D Acellular pertussis P Hepatitis B HB Inactivated pli vaccine POL Haemphilus influenzae type b - Hib Children six weeks up t tw years f age. Ntes: INFANRIX hexa became available September 1, 2016 fr the rutine Alberta Immunizatin Prgram. Related Resurces: Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Pli and Haemphilus influenzae type b Cnjugate Vaccine Infrmatin Sheet (September 1, 2016). References: Alberta Health. (2016, March 16). Alberta Immunizatin Plicy. Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus influenzae type b Cnjugate Cmbined Vaccine: INFANRIX hexa. Alberta Health, Health System Accuntability and Perfrmance Divisin. GlaxSmithKline. (2016, April 25). Prduct Mngraph. INFANRIX hexa : Cmbined diphtheria and tetanus txids, acellular pertussis, hepatitis B (recmbinant), inactivated plimyelitis and adsrbed cnjugated Haemphilus influenzae type b vaccine. Natinal Advisry Cmmittee n Immunizatin. (2016). Canadian Immunizatin Guide (Evergreen Editin). Ottawa, ON: Public Health Agency f Canada. Immunizatin Prgram Standards Manual Page 5 f 5 Ppulatin, Public and Indigenus Health

Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)

Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB) Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.214 Created

More information

Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine Biological Page (dtap)

Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine Biological Page (dtap) Diphtheria-Tetanus-Acellular Pertussis Cmbined Vaccine Bilgical Page (dtap) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.210 Created by: Apprved by: Prvince-wide Immunizatin Prgram Standards and

More information

Hepatitis B Vaccine Biological Page

Hepatitis B Vaccine Biological Page Hepatitis B Vaccine Bilgical Page Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.234 Created by: Apprved by: Prvince-wide Immunizatin Prgram Standards and Quality Prvince-wide Immunizatin Prgram, Standards

More information

Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib)

Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib) Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib) Section 7: Biological Product Information Standard #: 07.211 Created

More information

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038) Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December

More information

BOOSTRIX -POLIO: Diphtheria-Tetanus- Acellular Pertussis-Polio Combined Vaccine Biological Page (dtap-ipv)

BOOSTRIX -POLIO: Diphtheria-Tetanus- Acellular Pertussis-Polio Combined Vaccine Biological Page (dtap-ipv) BOOSTRIX -POLIO: Diphtheria-Tetanus- Acellular Pertussis-Polio Combined Vaccine Biological Page (dtap-ipv) Section 7: Biological Product Information Standard #: 07.213 Created by: Province-wide Immunization

More information

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038) Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December

More information

Diphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV)

Diphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV) Diphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV) Section 7: Biological Product Information Standard #: 07.212 Created by: Province-wide Immunization Program Standards

More information

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic

More information

Pediatric and adolescent preventive care and HEDIS *

Pediatric and adolescent preventive care and HEDIS * Pediatric and adlescent preventive care and HEDIS * * HEDIS is a registered trademark f the Natinal Cmmittee fr Quality Assurance (NCQA). UniCare Health Plan f West Virginia, Inc. Healthcare Effectiveness

More information

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE

Vaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están

More information

Section IA-Introduction

Section IA-Introduction Immunizatin Prgrams and Vaccine Preventable Diseases Service 655 West 12th Avenue Vancuver, BC V5Z 4R4 Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca Date: May 15, 2017 Administrative Circular: 2017:07

More information

Medical Student Immunization Requirements

Medical Student Immunization Requirements Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German

More information

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE

Vaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están

More information

Provider Information: Influenza VISs

Provider Information: Influenza VISs Prvider Infrmatin: Influenza VISs Thirteen influenza vaccine prducts are apprved fr use in the United States fr the 2014-15 influenza seasn: Name Manufacturer Age Range # f Strains Afluria bicsl 9 years

More information

Tetanus Prevention, Prophylaxis and Wound/Injury Management Standard

Tetanus Prevention, Prophylaxis and Wound/Injury Management Standard Tetanus Preventin, Prphylaxis and Wund/Injury Management Standard Sectin 8: Immunizatin f Special Ppulatins Standard #: 08.400 Created by: Apprved by: Prvince-wide Immunizatin Prgram, Standards and Quality

More information

PART III: CONSUMER INFORMATION

PART III: CONSUMER INFORMATION IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr ZERIT Stavudine This leaflet is Part III f a three-part Prduct Mngaph published when ZERIT was apprved fr sale in Canada and is designed specifically

More information

Tick fever is a cattle disease caused by any one of the following blood parasites:

Tick fever is a cattle disease caused by any one of the following blood parasites: Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus

More information

Polio Vaccine Biological Page

Polio Vaccine Biological Page Polio Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.300 Created by: Approved by: Province-wide Immunization Program Standards and Quality Province-wide Immunization Program,

More information

Immunisation and Disease Prevention Policy

Immunisation and Disease Prevention Policy Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER (Sanfi-Aventis France), NT001 Suppliers submissin f the SRA apprved text Octber 2016 Name f the medicinal prduct Text bx PACKAGE LEAFLET: INFORMATION FOR THE USER NOTEZINE 100 mg, scred tablets Diethylcarbamazine

More information

Safety of HPV vaccination: A FIGO STATEMENT

Safety of HPV vaccination: A FIGO STATEMENT FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have

More information

Table of Contents. 1.0 INFANRIX hexa VACCINE...3

Table of Contents. 1.0 INFANRIX hexa VACCINE...3 Table of Contents 1.0 INFANRIX hexa VACCINE...3 1.1 What is INFANRIX hexa vaccine?...3 1.2 When will INFANRIX hexa be introduced?...3 1.3 What is the difference between INFANRIX hexa and Pediacel?...3

More information

HPV VACCINATION IN SANDYFORD SERVICES

HPV VACCINATION IN SANDYFORD SERVICES HPV VACCINATION IN SANDYFORD SERVICES 1. General infrmatin n HPV Vaccinatin 2. HPV vaccinatin in females 3. Yung Wmen Only 4. HPV vaccinatin in MSM 1. General infrmatin General Infrmatin fr clinicians

More information

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate Package leaflet: Infrmatin fr the user Daceptn 5 mg/ml Slutin fr infusin Apmrphine hydrchlride hemihydrate Read all f this leaflet carefully befre yu start using this medicine because it cntains imprtant

More information

Pneumococcal 13-valent Conjugate Vaccine Biological Page

Pneumococcal 13-valent Conjugate Vaccine Biological Page Pneumococcal 13-valent Conjugate Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.291 Created by: Province-wide Immunization Program Standards and Quality Approved by: Province-wide

More information

ENA Topic Brief. Adult Immunizations. Key Information

ENA Topic Brief. Adult Immunizations. Key Information ENA Tpic Brief Key Infrmatin Immunizatins are vital fr d isease preventin and health prmtin. The CDC prvides recmmendatins fr adult immunizatins. Infrmatin n vaccines are available at n cst frm the CDC.

More information

Methadone Maintenance Treatment for Opioid Dependence

Methadone Maintenance Treatment for Opioid Dependence POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin

More information

Flu Season Key Points ( )

Flu Season Key Points ( ) 2014-2015 Flu Seasn Key Pints (10-31-14) Cntents Overarching Framewrk f CDC Influenza Messaging... 3 Take 3 Messages... 3 Statements fr General Audiences... 4 Disease... 4 Vaccinatin... 6 Vaccinatin Timing...

More information

Annex III. Amendments to relevant sections of the Product Information

Annex III. Amendments to relevant sections of the Product Information Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t

More information

Dear Student, IMMUNIZATION RECORD INSTRUCTIONS

Dear Student, IMMUNIZATION RECORD INSTRUCTIONS Dear Student, Welcme t the University f Chicag! The State f Illinis and University regulatins require students t prvide prf f required immunizatins prir t registratin fr classes. In rder t cmplete this

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.

More information

MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion

MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new

More information

Original Policy Date 12:2013

Original Policy Date 12:2013 MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our

More information

CDC Influenza Division Key Points November 7, 2014

CDC Influenza Division Key Points November 7, 2014 In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates

More information

Use of Infanrix -IPV+Hib in the infant primary immunisation schedule

Use of Infanrix -IPV+Hib in the infant primary immunisation schedule Use of Infanrix -IPV+Hib in the infant primary immunisation schedule An update for registered healthcare practitioners July 2014 Quality Education for a Healthier Scotland 1 Acknowledgments Many thanks

More information

Request for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax

Request for Prior Authorization for Click here to enter text. Website Form   Submit request via: Fax Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus

More information

Action plan: serialisation of Nordic packages focus on Product Codes

Action plan: serialisation of Nordic packages focus on Product Codes 19.6.2017, versin 5 Actin plan: serialisatin f Nrdic packages fcus n Prduct Cdes The aim f this dcument is t help pharma cmpanies t prepare fr prduct cde changes and t be able t maintain prduct cdes in

More information

PATIENT INFORMATION. effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems.

PATIENT INFORMATION. effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems. PATIENT INFORMATION capsules, fr ral use fr ral suspensin What is TAMIFLU? TAMIFLU is a prescriptin medicine used t: treat the flu (influenza) in peple 2 weeks f age and lder wh have had flu symptms fr

More information

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment

More information

MEDICATION GUIDE. (fingolimod) capsules

MEDICATION GUIDE. (fingolimod) capsules MEDICATION GUIDE GILENYA (je-len-yah) (finglimd) capsules Read this Medicatin Guide befre yu start using GILENYA and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take the

More information

Policy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning

Policy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening

More information

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations Implementatin f G6PD testing and radical cure in P. vivax endemic cuntries: cnsideratins Malaria Plicy Advisry Cmmittee Geneva, Switzerland 16-18 September 2015 1 WHO Guidelines n Radical Cure WHO guidelines

More information

Infection Control Guidelines for Cabin Crew Members on Commercial Aircraft

Infection Control Guidelines for Cabin Crew Members on Commercial Aircraft Infectin Cntrl Guidelines fr Cabin Crew Members n Cmmercial Aircraft PURPOSE These guidelines prvide cabin crew members (flight attendants) with practical measures t prtect themselves, passengers, and

More information

Washington University Physician Network Campus Box Duncan Ave, Ste. 301 St. Louis, MO Phone: (314)

Washington University Physician Network Campus Box Duncan Ave, Ste. 301 St. Louis, MO Phone: (314) Washingtn University Physician Netwrk Campus Bx 8221 4240 Duncan Ave, Ste. 301 St. Luis, MO 631110 Phne: (314) 273-0600 August 5, 2016 RE: WUPN/CHA Grup Purchasing Prgram New GSK Price Change Ntificatin

More information

Package leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium

Package leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium Package leaflet: Infrmatin fr the user Fragmin Graduated Syringe 10,000 IU/ml Slutin fr Injectin dalteparin sdium Read all f this leaflet carefully befre yu start using this medicine because it cntains

More information

Widening of funding restrictions for rituximab and eltrombopag

Widening of funding restrictions for rituximab and eltrombopag 20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding

More information

Benepali (etanercept): Brief training on additional Risk Minimisation Measures

Benepali (etanercept): Brief training on additional Risk Minimisation Measures Benepali (etanercept): Brief training n additinal Risk Minimisatin Measures Slide Deck fr Healthcare Prfessinal (HCP) Training Versin 9.0; 22 January 2016 UK/IE 1 Benepali (etanercept) This medicine is

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting

More information

Influenza (Flu) Fact Sheet

Influenza (Flu) Fact Sheet Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder

More information

INSTRUCTIONS FOR USE ZINBRYTA (zin-bry-tuh) (daclizumab) Injection, for Subcutaneous Use Single-Dose Prefilled Syringe 150 mg

INSTRUCTIONS FOR USE ZINBRYTA (zin-bry-tuh) (daclizumab) Injection, for Subcutaneous Use Single-Dose Prefilled Syringe 150 mg INSTRUCTIONS FOR USE ZINBRYTA (zin-bry-tuh) (daclizumab) Injectin, fr Subcutaneus Use Single-Dse Prefilled Syringe 150 mg Read this Instructins fr Use befre yu start using ZINBRYTA and each time yu get

More information

ALCAT FREQUENTLY ASKED QUESTIONS

ALCAT FREQUENTLY ASKED QUESTIONS 1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age

More information

Triumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media

Triumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based

More information

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training

Iowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training Iwa Early Peridic Screening, Diagnsis and Treatment Care fr Kids Prgram Prvider Training The Early Peridic Screening, Diagnsis and Treatment (EPSDT) Care fr Kids prgram is Iwa s Medicaid prgram fr children.

More information

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

Human papillomavirus (HPV) refers to a group of more than 150 related viruses. HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between

More information

cerliponase alfa (Brineura )

cerliponase alfa (Brineura ) cerlipnase alfa (Brineura ) Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany ), unless

More information

DRAFT Policy for the Management of Ear Wax

DRAFT Policy for the Management of Ear Wax Clinical Cmmissining Grup (CCG) Treatment Plicy NHS Birmingham and Slihull Clinical Cmmissining Grup NHS Sandwell and West Birmingham Clinical Cmmissining Grup DRAFT Plicy fr the Management f Ear Wax 1

More information

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the

More information

Frequently asked questions: Influenza A (H1N1)v

Frequently asked questions: Influenza A (H1N1)v July 30 th 2009 V1.0 Frequently asked questins: Influenza A (H1N1)v (Swine Flu) infrmatin fr parents The fllwing advice is fr parents f children in all educatinal institutins, including crèches, childcare,

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

Immunization for Special Populations

Immunization for Special Populations Newfundland and Labradr Immunizatin Manual Sectin 8 Immunizatin fr Special Ppulatins 8.1 Immunizatin Pst Bne Marrw Transplant/Stem Cell Transplant... 1-1 8.2 Immunizatin f Asplenic Ppulatin... 2-1 8.3

More information

PACKAGE LEAFLET INFORMATION FOR THE PATIENT

PACKAGE LEAFLET INFORMATION FOR THE PATIENT PACKAGE LEAFLET INFORMATION FOR THE PATIENT AMPICILLIN 125mg/5ml and 250mg/5ml ORAL SUSPENSION Please read all f this leaflet carefully befre yu start taking this medicine because it cntains imprtant infrmatin

More information

Immunization Competencies Education Program

Immunization Competencies Education Program Immunizatin Cmpetencies Educatin Prgram Adapted by: Michael Bivin, B Pharm Susan Bwles, BSc Phm, PharmD, MSc Danielle Grenier, MD, FRCPC Ian Gemmill, MD, CCFP, FCFP, FRCPC Alex Henteleff, BN, Med Expert

More information

CDC Influenza Division Key Points MMWR Updates February 20, 2014

CDC Influenza Division Key Points MMWR Updates February 20, 2014 CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February

More information

MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP

MEDICATION GUIDE Pioglitazone and Metformin Hydrochloride (PYE o GLI ta zone and met FOR min HYE-droe- KLOR-ide)Tablets, USP MEDICATION GUIDE Piglitazne and Metfrmin Hydrchlride (PYE GLI ta zne and met FOR min HYE-dre- KLOR-ide)Tablets, USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride

More information

Hepatitis B Immune Globulin Biological Page

Hepatitis B Immune Globulin Biological Page Hepatitis B Immune Globulin Biological Page Section 7: Biological Product Information Standard #: 07.233 Created by: Approved by: Province-wide Immunization Program Standards and Quality Province-wide

More information

MEDICATION GUIDE. (canagliflozin) Tablets

MEDICATION GUIDE. (canagliflozin) Tablets MEDICATION GUIDE INVOKANA (in-v-kahn-uh) (canagliflzin) Tablets What is the mst imprtant infrmatin I shuld knw abut INVOKANA? INVOKANA can cause imprtant side effects, including: Dehydratin. INVOKANA can

More information

MEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP

MEDICATION GUIDE Pioglitazone (pie-oh-glit-ah-zohn) and Metformin (met-fore-min) Hydrochloride Tablets USP MEDICATION GUIDE Piglitazne (pie-h-glit-ah-zhn) and Metfrmin (met-fore-min) Hydrchlride Tablets USP Read this Medicatin Guide carefully befre yu start taking piglitazne and metfrmin hydrchlride tablets

More information

Package leaflet: Information for the user. Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Solution for injection dalteparin sodium

Package leaflet: Information for the user. Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Solution for injection dalteparin sodium Package leaflet: Infrmatin fr the user Fragmin 10,000 IU/1 ml and 10,000 IU/4 ml Slutin fr injectin dalteparin sdium Read all f this leaflet carefully befre yu start using this medicine because it cntains

More information

Dear University of Chicago Student,

Dear University of Chicago Student, Dear University f Chicag Student, The state f Illinis and the University f Chicag require students t have prf f immunity fr certain diseases including Measles (Rubela), Mumps, Rubella (German Measles)

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY

More information

You may have a higher risk of bleeding if you take warfarin sodium tablets and:

You may have a higher risk of bleeding if you take warfarin sodium tablets and: MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain

More information

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select

More information

MEDICATION GUIDE. (Interferon alfa-2b)

MEDICATION GUIDE. (Interferon alfa-2b) MEDICATION GUIDE INTRON A (In-trn-aye) (Interfern alfa-2b) Read this Medicatin Guide befre yu start taking INTRON A, and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take

More information

MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID?

MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID? MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidmide) capsules What is the mst imprtant infrmatin I shuld knw abut REVLIMID? Befre yu begin taking REVLIMID, yu must read and agree t all f the instructins

More information

2017 Optum, Inc. All rights reserved BH1124_112017

2017 Optum, Inc. All rights reserved BH1124_112017 1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases

More information

Completing the NPA online Patient Safety Incident Report form: 2016

Completing the NPA online Patient Safety Incident Report form: 2016 Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019

More information

Obesity/Morbid Obesity/BMI

Obesity/Morbid Obesity/BMI Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin

More information

SECTION O. MEDICATIONS

SECTION O. MEDICATIONS SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:

More information

Child and Adult Preventive Care Services

Child and Adult Preventive Care Services Child and Adult Preventive Care Services Adult and Child Preventive Care Services will meet the requirements as determined by federal and state law. Cvered preventive care services prvided by a Participating

More information

Commissioning Policy: South Warwickshire CCG (SWCCG)

Commissioning Policy: South Warwickshire CCG (SWCCG) Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding

More information

Medication Guide SIGNIFOR [sig-na-for] (pasireotide) Injection

Medication Guide SIGNIFOR [sig-na-for] (pasireotide) Injection Medicatin Guide SIGNIFOR [sig-na-fr] (pasiretide) Injectin Read this Medicatin Guide befre yu start using SIGNIFOR and each time yu get a refill. There may be new infrmatin. This infrmatin des nt take

More information

77 WHO/IPA workshop on Immunisation

77 WHO/IPA workshop on Immunisation 77 WHO/IPA wrkshp n Immunisatin cst/efficacy f either f them des nt justify their rutine use. Cntents f such diseases shuld be within the respnsibilities f the Epidemilgy Department. XVII INTERNATIONAL

More information

Hepatitis B Vaccine Biological Page

Hepatitis B Vaccine Biological Page Hepatitis B Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.234 Created by: Approved by: Province-wide Immunization Program Standards and Quality Province-wide Immunization

More information

MEDICATION GUIDE. Reference ID:

MEDICATION GUIDE. Reference ID: MEDICATION GUIDE GLYXAMBI (glik-sam-bee) (empagliflzin and linagliptin) Tablets Read this Medicatin Guide carefully befre yu start taking GLYXAMBI and each time yu get a refill. There may be new infrmatin.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is

More information

Section 6 Students School District No. 71 (Comox Valley)

Section 6 Students School District No. 71 (Comox Valley) Sectin 6 Students Schl District N. 71 (Cmx Valley) Administrative Prcedure 6011 MR2 Allergies and Anaphylaxis 1. Intrductin The Bard f Educatin expects schls t reasnably accmmdate students with medically

More information

Yescarta (axicabtagene ciloleucel) (Intravenous)

Yescarta (axicabtagene ciloleucel) (Intravenous) Yescarta (axicabtagene cilleucel) (Intravenus) Last Review Date: 10/31/2017 Date f Origin: 10/31/2017 Dates Reviewed: 10/2017 Dcument Number: IC-0333 I. Length f Authrizatin Cverage will be prvided fr

More information

This information shows what new challenges are likely to require prevention efforts moving forward.

This information shows what new challenges are likely to require prevention efforts moving forward. Release f CDC s Healthcare-Assciated Infectins (HAI) Pint Prevalence Survey and Annual Natinal and State HAI Prgress Reprt Embarged until: Wednesday, March 26 th at 12 nn ET Key Messages Overall These

More information

Fee Schedule - Home Health Care- 2015

Fee Schedule - Home Health Care- 2015 Fee Schedule - Hme Health Care- 2015 01/01/2015 1600 E Century Ave Ste 1 PO Bx 5585 Bismarck ND 58506-5585 www.wrkfrcesafety.cm Cpyright Ntice The five character cdes included in the Nrth Dakta Fee Schedule

More information

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this

More information

Package leaflet: Information for the user. GASTROGRAFIN GASTROENTERAL SOLUTION Sodium amidotrizoate and meglumine amidotrizoate

Package leaflet: Information for the user. GASTROGRAFIN GASTROENTERAL SOLUTION Sodium amidotrizoate and meglumine amidotrizoate Due t regulatry changes, the cntent f the fllwing Patient Infrmatin Leaflet may vary frm the ne fund in yur medicine pack. Please cmpare the 'Leaflet prepared/revised date' twards the end f the leaflet

More information

Rate Lock Policy. Contents

Rate Lock Policy. Contents Rate Lck Plicy Cntents Rate Lcks... 2 Rate Lck Cnfirmatin... 2 Lck Term... 2 Pre-Lck... 2 Maximum Qualified Rate... 3 Extensins... 3 Cst t Extend... 3 Relcks... 4 Re-Negtiatin r Flat Dwn Plicy... 4 Prgram

More information

Section V: Immunization

Section V: Immunization Michigan Lcal Public Health Accreditatin Prgram Tl 2014 MPR Indicatr Guide Sectin V: Immunizatin MPR 1 The lcal health department shall ffer immunizatin services t the public fllwing a cmprehensive plan

More information

FDA Dietary Supplement cgmp

FDA Dietary Supplement cgmp FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes

More information

Rituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY

Rituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY Rituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY 1. Backgrund and indicatins Rituximab is a mnclnal antibdy that wrks by remving B-cells (a type f white bld cell that prduce antibdies). The aim f the B cell

More information

US Public Health Service Clinical Practice Guidelines for PrEP

US Public Health Service Clinical Practice Guidelines for PrEP Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S

More information